Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.81 |
| ▸ | PGR | P06401 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | IKBKB | O14920 | 1/20 | 0.81 |
| ▸ | CHUK | O15111 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.81 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxibetasol SCHEMBL140220 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL11328088 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL11885535 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL11328085 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL13754704 | 1.00 | NR3C1 (0.85) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL19026488 | 0.96 | NR3C1 (0.80) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| Doxibetasol SCHEMBL19026536 | 0.96 | NR3C1 (0.80) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL18379414 | 0.92 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL19764184 | 0.92 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 | |
| SCHEMBL19308807 | 0.92 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-12-30 | — | — | US | claimed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | claimed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | claimed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | claimed |
| WO-2016145186-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2015143190-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-09-24 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140336162-A1 | LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS | WARSAW ORTHOPEDIC INC (US) | 2014-11-13 | — | — | US | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| CN-1599613-A | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX INC (US) | 2005-03-23 | — | — | CN | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| EP-1414466-A1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-05-06 | — | — | EP | claimed |
| US-20040072732-A1 | Use of ramoplanin to treat diseases associated with the use of antibiotics | NANOSHIFT, LLC | 2004-04-15 | — | — | US | claimed |
| WO-2003103699-A1 | USE OF RAMOPLANIN TO TREAT DISEASES ASSOCIATED WITH THE USE OF ANTIBIOTICS | VICURON PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2003092617-A2 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | ZALICUS INC. | 2003-04-24 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
| WO-2003006026-A1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-01-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | LTA4H, ALOX15B, LTB4R | NR3C1 736/4885HIF1A 1354/4885CYP3A4 423/4885 |
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | IL6, FKBP1B, NR3C1 | NR3C1 3/4885HIF1A 2385/4885CYP3A4 333/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | NR3C1 32/4885HIF1A 1616/4885CYP3A4 995/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | NR3C1 290/4885HIF1A 836/4885CYP3A4 3907/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | NR3C1 290/4885HIF1A 836/4885CYP3A4 3907/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | NR3C1 413/4885HIF1A 1602/4885CYP3A4 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.